Cytokinetics Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Cytokinetics Inc in the market include pharmaceutical companies such as Amgen, Biogen, and Novartis. These companies also specialize in the development of cutting-edge therapies and drugs for various medical conditions. However, Cytokinetics Inc distinguishes itself through its novel approach to drug discovery, focusing on the field of muscle biology and developing potential treatments for diseases related to muscle dysfunction. With its innovative research and development strategies, Cytokinetics Inc aims to make significant contributions to the pharmaceutical industry and provide solutions that address unmet medical needs.

Cytokinetics Inc is a renowned biopharmaceutical company specializing in the discovery and development of muscle biology-focused therapies. Established in 1997, the company has emerged as a leading player in the field, harnessing the power of sarcomere-directed drug candidates. Cytokinetics' innovative research and development aim to address diseases associated with muscle impairment and dysfunction. With a strong focus on cardiovascular and neuromuscular diseases, Cytokinetics Inc continues to progress its pipeline of potential treatments with the goal of improving patients' lives. Their commitment to scientific advancement and clinical collaboration places Cytokinetics Inc at the forefront of efforts to tackle serious medical conditions.

Cytokinetics Inc has achieved significant milestones in its journey. One notable achievement is the development of omecamtiv mecarbil, a potential treatment for heart failure. The company has successfully completed various clinical trials, demonstrating promising results in improving cardiac function. Additionally, Cytokinetics Inc has advanced its research in muscle biology and therapeutics, leading to collaborations with renowned pharmaceutical companies and medical institutions. Furthermore, the company's continuous dedication to innovation and scientific excellence has resulted in numerous patents and publications. These milestones highlight Cytokinetics Inc's commitment to delivering innovative solutions and advancing the field of cardiac and skeletal muscle disorders.

Cytokinetics Inc is primarily present in the United States.

Cytokinetics Inc is committed to improving the lives of patients by developing innovative therapies in the field of muscle biology. The company's core values include integrity, collaboration, and dedication to scientific excellence. Cytokinetics is driven by a corporate philosophy that emphasizes scientific rigor, patient-centricity, and a strong commitment to advancing medical knowledge. By working closely with key stakeholders, including healthcare professionals and patients, Cytokinetics aims to address unmet medical needs and make a positive impact on global healthcare. With its cutting-edge research and development efforts, Cytokinetics Inc strives to bring new treatment options to patients suffering from serious diseases and disorders affecting muscle function.

Analysts currently set an average price target of 91.56 USD for the Cytokinetics stock (median: 89.76 USD), implying +12.5 % versus the latest price. The consensus is based on 26 analyst ratings.

Cytokinetics Analyst Price Targets 2026

26 analysts currently rate the Cytokinetics stock: 22 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Cytokinetics to generate revenue of 113.58 M USD and earnings per share of -6.31 USD.

Cytokinetics Analyst Price Targets 2026

Converted at the current exchange rate, the Cytokinetics share trades at 68.26 EUR (78.71 USD).

The Cytokinetics share (CYTK) is listed on 5 stock exchanges, including: NASDAQ (CYTK), Frankfurt (KK3A.F), München (KK3A.MU), Düsseldorf (KK3A.DU), SIX (Zürich) (KK3A.SW).

Cytokinetics Inc. is a biopharmaceutical company based in South San Francisco, California. The company specializes in the development of novel therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. It utilizes expertise in cell biology, medical technology, and drug development to create precision medicine therapies tailored to clinical needs. The company has two main divisions: Cardiovascular and Neuromuscular. The Cardiovascular division focuses on developing therapeutics for diseases of the heart muscle and blood vessels. This includes heart muscle diseases such as heart failure and arrhythmias, as well as vascular diseases such as peripheral arterial disease and pulmonary arterial hypertension. The Neuromuscular division specializes in developing therapeutics for diseases of the skeletal muscle. This includes neuromuscular diseases such as spinal muscular atrophy, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy. Cytokinetics develops its therapeutics using an innovative class of drugs known as myosin activators. A myosin activator is a substance that activates the enzyme myosin, which is responsible for muscle contraction. By activating myosin, the muscle can work better and more effectively. One of Cytokinetics' key products is the investigational drug Omecamtiv Mercabil. It is an oral myosin activator for the treatment of heart failure. Omecamtiv's mechanism is aimed at increasing the contractile force of the heart muscle to improve blood flow and pumping. The continuous research and development of drugs like Omecamtiv Mercabil have the potential to usher in a new era of treatment for cardiovascular diseases. Cytokinetics also has a partnership with Astellas Pharma Inc. for the joint development of Reldesemtiv for spinal muscular atrophy, CK-274 for hypertrophic cardiomyopathy, and other neuromuscular indications. Collaborating with partners increases the likelihood of rapid and successful drug development and accelerates market introduction. Cytokinetics' business model is based on partnerships with other companies to accelerate the research and development of therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. By leveraging innovative technologies and platforms, and integrating data, human experience, and scientific intelligence, Cytokinetics brings novel medicines to market that could improve the quality of life for millions of patients worldwide.

The expected revenue of Cytokinetics is 113.58 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cytokinetics is -772.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cytokinetics is currently -12.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cytokinetics stock.

The price-to-sales ratio (P/S) of Cytokinetics is currently 84.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cytokinetics stock.

The Eulerpool Quality Score for Cytokinetics is 2/10.

The ISIN of Cytokinetics is US23282W6057. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cytokinetics is A1W1KK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cytokinetics is CYTK. The ticker symbol is used to trade Cytokinetics shares on the stock exchange.

Cytokinetics paid dividends every year for the past 0 years.

Cytokinetics is assigned to the 'Health' sector.

The dividends of Cytokinetics are distributed in USD.